Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization-Reference-Cited by-全球学者库

Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Published:2021-07-05 Issue:11 Volume:36 Page:3196-3203
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Ho Shu‐Yein¹²³,Liu Po‐Hong³⁴,Hsu Chia‐Yang³⁵,Ko Chih‐Chieh³⁶,Huang Yi‐Hsiang³⁶⁷^ORCID,Su Chien‐Wei³⁶^ORCID,Lee Rheun‐Chuan³⁸,Tsai Ping‐Hsing²,Hou Ming‐Chih³⁶^ORCID,Huo Teh‐Ia²³⁹^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology Min‐Sheng General Hospital Taoyuan City Taiwan

2. Department of Medical Research Taipei Veterans General Hospital Taipei Taiwan

3. Faculty of Medicine National Yang Ming Chiao Tung University Taipei Taiwan

4. Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA

5. Division of Gastroenterology and Hepatology University of Michigan Ann Arbor Michigan USA

6. Department of Medicine Taipei Veterans General Hospital Taipei Taiwan

7. Institute of Clinical Medicine National Yang Ming Chiao Tung University Taipei Taiwan

8. Department of Radiology Taipei Veterans General Hospital Taipei Taiwan

9. Institute of Pharmacology National Yang Ming Chiao Tung University Taipei Taiwan

Funder

Taipei Veterans General Hospital

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15593

Reference30 articles.

1. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention

2. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization

3. AASLD guidelines for the treatment of hepatocellular carcinoma

4. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

5. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes;HPB;2023-07

2. Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection;Langenbeck's Archives of Surgery;2023-06-29

3. Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate‐stage hepatocellular carcinoma undergoing chemoembolization;Cancer Imaging;2023-05-30

4. FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE;Frontiers in Medicine;2023-05-02

5. Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver Cancer stages;Langenbeck's Archives of Surgery;2023-05-01